IMiDs and Celmods Enhance Antigen Presentation Via MHC Class 1 - a Potential Novel Immunostimulatory Effect

抗原呈递 MHC II级 班级(哲学) 免疫学 介绍(产科) 抗原 川东北74 主要组织相容性复合体 医学 免疫系统 计算机科学 T细胞 人工智能 放射科
作者
Shannon Martin,Yakinthi Chrisochoidou,Andreia S. Margarido,Fernando J. Sialana,Salomon Morales,Marc Leiro,Yigen Li,Sarah Bird,Konstantinos Mitsopoulos,Esther N. Arwert,Charlotte Pawlyn
出处
期刊:Blood [Elsevier BV]
卷期号:144 (Supplement 1): 3284-3284 被引量:2
标识
DOI:10.1182/blood-2024-203340
摘要

Introduction Immunomodulatory drugs (IMiDs) such as Lenalidomide (Len) have a direct impact on myeloma (MM) cells by functioning as a molecular glue, binding to a CRL4CRBN E3 ubiquitin ligase (cereblon) and leading to degradation of neo-substrates including ikaros (IKZF1) and aiolos (IKZF3). This results in downregulation of IRF4/MYC and MM cell death. IMiDs have also been shown to have direct action on the immune system, including T cells via upregulation of IL-2. We hypothesized that the enhanced degradation of neo-substrates in the tumour cell could be associated with a third mechanism of action, through altered antigen presentation of the neo-substrate degradation products as peptides via MHC class I (MHC-I), leading to upregulation of CD8+ T cell immunosurveillance. Additionally, we hypothesized that the novel cereblon binding agents (CELMoDs), such as Mezigdomide (Mezi), would lead to enhanced altered antigen presentation and a greater induced T cell response compared to IMiDs. Methods H929 cells were treated with either 10uM Len, 0.01uM Mezi or DMSO. IKZF1/IKZF3 degradation was measured via Western blot, after 2 and 24hrs. Global HLA levels were measure via flow cytometry after 24 hours of drug exposure with a pan HLA-ABC antibody. Subsequently, 1x10^8 H929 cells per condition were incubated with 10uM Len, 0.01uM Mezi or DMSO for 2 hours and 24hours. Cells were harvested and lysed in 1% CHAPS buffer. MHC-I peptide complexes were then isolated via incubation with bead/antibody complex, and the peptides then eluted and dried. MHC-peptides were labelled with tandem mass tags (TMT) to facilitate relative quantification via mass spectrometry (TMT-MS2). Predicted binding was analysed using NetMHC website. Normalised peptide abundance values were compared to their relative DMSO control using Log2 fold change (FC). Results Degradation of IKZF1 and IKZF3 was confirmed at 2 and 24hrs. There was greater degradation with Mezi compared to Len and at the longer time point. Global MHC-I expression did not change following incubation with Len and Mezi, as seen by flow. This indicates that any upregulated peptides subsequently identified by MS were not due to upregulation of MHC-I itself. After isolation of MHC-I bound peptides and MS identification, a total of 7809 peptides (between 8-15 amino acids in length) from 3901 protein sources were identified across all samples. Most of the peptides were 9-mers (53.7%), consistent with the literature for MHC-I isolated peptides. 82% of peptides had high predicted binding for all the MHC-I alleles for H929 (HLA-A03:01, HLA-A24:02, HLA-B07:02, HLA-B18:01, HLA-C07:02). All peptides with high predicted binding and consistently upregulated by a log2FC of at least 0.3 in all three replicates were considered further. Both Len and Mezi led to enhanced antigen presentation compared to DMSO, with more unique peptides presented at 24hrs vs 2hrs and with Mezi vs Len (Len 2hrs 2 peptides, Len 24hrs 24 peptides, Mezi 2hrs 10 peptides, Mezi 24hrs 40 peptides). 3 peptides (derived from proteins IKZF3, TMEM147 and ITGB7) were seen to have an increased expression across more than one treatment condition, and3 additional peptide sequences (derived from proteins APOL6 and ITGB7) corresponded to the same protein source across different treatment conditions. All peptides derived from the IKZF3 and IKZF1 proteins were explored in more detail. Across the dataset 4 distinct peptides from IKZF1 (x1) and IKZF3 (x3) were identified. Their pulldown was enriched after incubation with Len (IKZF1: mean Log2 FC 2hrs -0.04, 24 hrs 0.44, IKZF3 mean Log2 FC 2hrs -0.12, 0.07, 0.34, 24 hrs -0.09, 0.16, 0.40) and Mezi (IKZF1: mean Log 2 FC 2hrs 0.3, 24hrs 0.43, IKZF3 mean Log2 FC 2hr 0.17, 0.49, 0.53, 24 hrs 0.18, 0.43, 0.63) compared to DMSO control, most marked for the 24hour time point and with Mezi. These, and the additional peptides of interest from protein sources TMEM147, ITGB7 and APOL6 will be analysed in immunogenicity assay to confirm stimulation of CD8+ T cells. Discussion Our data suggest that myeloma cells can present peptides from the known neo-substrates IKZF1 and IKZF3, along with additional peptides, after IMiD/CELMoD therapy via MHC-I. This occurred to a greater extent with the CELMoD Mezi compared to the IMiD Len. Experiments to assess the immunogenicity of the presented peptides are ongoing. These data highlight a potential novel mechanism by which IMiDs and CELMoDs may stimulate the immune system.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Yob完成签到,获得积分10
1秒前
乐乐的应助被zyy采纳,获得30
2秒前
规划计划完成签到 ,获得积分10
2秒前
科研通AI6.2的应助被tjl采纳,获得10
3秒前
邱燈完成签到,获得积分10
4秒前
SciGPT的应助被外向的大狮子采纳,获得10
5秒前
5秒前
天天快乐的应助被6666采纳,获得10
5秒前
伶俐绿柏完成签到,获得积分10
6秒前
6秒前
传奇3的应助被JF123_采纳,获得10
6秒前
Owen的应助被yansiyi采纳,获得20
7秒前
eerrtt完成签到,获得积分10
8秒前
8秒前
8秒前
松下完成签到,获得积分10
8秒前
9秒前
打打的应助被廖翰彬采纳,获得10
9秒前
9秒前
Qiiiyoung完成签到,获得积分10
9秒前
张远幸发布了新的文献求助10
10秒前
10秒前
10秒前
peng完成签到,获得积分10
10秒前
11秒前
缺粥发布了新的文献求助10
12秒前
华仔的应助被吴呜呜采纳,获得10
13秒前
所所的应助被1111采纳,获得10
13秒前
Micheallee完成签到,获得积分10
13秒前
Hello的应助被老汉憨憨采纳,获得10
14秒前
科研通AI6.4的应助被dde采纳,获得30
14秒前
15秒前
个性天晴完成签到 ,获得积分10
16秒前
16秒前
鲤鱼鑫磊发布了新的文献求助10
16秒前
丘比特的应助被zyy采纳,获得30
16秒前
111发布了新的文献求助10
16秒前
17秒前
科研通AI65的应助被西北采纳,获得10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187362
求助须知:如何正确求助?哪些是违规求助? 9575478
关于积分的说明 21841431
捐赠科研通 7785067
什么是DOI,文献DOI怎么找? 3434943
关于科研通互助平台的介绍 2559401
邀请新用户注册赠送积分活动 2481820